RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Reprogramming of lipid metabolism during hepatocarcinogenesis is not well elucidated. Here, we aimed to explore pivotal RNA-binding motif proteins (RBMs) in lipid metabolism and their therapeutic potential in hepatocellular carcinoma (HCC). Through bioinformatic analysis, we identified RBM45 as a critical gene of interest among differentially expressed RBMs in HCC, with significant prognostic relevance. RBM45 influenced the malignant biological phenotype and lipid metabolism of HCC cells. Mechanically, RBM45 promotes de novo lipogenesis in HCC by directly targeting two key enzymes involved in long-chain fatty acid synthesis, ACSL1 and ACSL4. RBM45 also targets Rictor, which has been demonstrated to modulate lipid metabolism profoundly. RBM45 also aided lipid degradation through activating a key fatty acid β oxidation enzyme, CPT1A. Thus, RBM45 boosted lipid synthesis and decomposition, indicating an enhanced utility of lipid fuels in HCC. Clinically, body mass index was positively correlated with RBM45 in human HCCs. The combination of a PI3K/AKT/mTOR pathway inhibitor in vitro or Sorafenib in orthotopic liver cancer mouse models with shRBM45 has a more significant therapeutic effect on liver cancer than the drug alone. In summary, our findings highlight the versatile roles of RBM45 in lipid metabolism reprogramming and its therapeutic potential in HCC. Lipids induced RBM45 expression. In turn, RBM45 promoted the utility of lipid in HCCs through accelerating both de novo lipogenesis and fatty acid β oxidation, which required the participation of Rictor, a core component of mTORC2 that has been demonstrated to modulate lipid metabolism potently, as well as ACSL1/ACSL4, two key enzymes of long-chain fatty acid synthesis. When the first-line chemotherapy drug sorafenib is combined with a PI3K/AKT/mTOR pathway inhibitor (MK2206 is an AKT inhibitor, rapamycin is a mTOR inhibitor, and inhibiting RBM45 can significantly inhibit Rictor), cell cycle, proliferation, lipid metabolism reprogramming, and hepatocarcinogenesis can be significantly inhibited, while apoptosis can be significantly enhanced.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BA treatment also reduced TG and total cholesterol content in liver LDs.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [147]
In the citing paper
“Notably, bempedoic acid (BA) works as an ACLY inhibitor, which is clinically used as a plasma cholesterol-lowering drug.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [147]
In the citing paper
“It effectively lowers LDL-cholesterol and reduces CV risk without muscle-related side effects.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [147]
In the citing paper
“BA is a prodrug that requires activation by a liver-specific enzyme, very long-chain ACSL1.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [147]
In the citing paper
“BA is a particularly important therapeutic agent, as it simultaneously inhibits cholesterol synthesis and DNL, making it potentially effective for treating MASH while also improving major CV outcomes [146-148].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [147]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695 · cited 1×
“Lipid metabolism reprogramming is known to associated with ferroptosis [33], where lipogenic enzymes enrich cellular membranes with long polyunsaturated fatty acids, rendering cells susceptible to iron-induced lipid hydroperoxides [34 – 36].”
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“NAFLDhas become the predominant chronic liver disease worldwide, contributing to 15% of HCC cases [53, 54].”
Lipid rafts as a membrane-organizing principle
Lingwood, D., & Simons, K. (2010) · Science · doi:10.1126/science.1174621 · Cited by 4,417 · cited 1×
“Our study has unveiled that FFA stimulation could elevate RBM45 levels, possibly through mechanisms like G protein-coupled fatty acid receptors (FFARs) activation and lipid rafts changes [56, 57].”
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293 · cited 1×
“In response to lipid-induced oxidative stress, tumor cells may elevate antioxidant defenses by tweaking pathways like autophagy, forming a network that dampens the impact of oxidative stress [35].”
Evidence for the Formation of Symmetric and Asymmetric DLPC-DAPC Lipid Bilayer Domains
Ritter, M., Schmidt, S., Jakab, M., Paulmichl, M., & Henderson, R. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350122 · Cited by 3,923
Cited by
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
ACSL4 at the helm of the lipid peroxidation ship: a deep-sea exploration towards ferroptosis
Jiang, Y., Zhang, M., & Sun, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1594419 · Cited by 88
Yu, S., Sun, Z., Ju, T., Liu, Y., Mei, Z., Wang, C., Qu, Z., Li, N., Wu, F., Liu, K., et al. (2024) · Advanced Science · doi:10.1002/advs.202308769 · Cited by 44
Self-citationeIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.
Zhou, S., Zhang, L.-R., You, Y., Yu, K., Tie, X., Gao, Y., Chen, Y.-N., Yao, F., Zhang, R.-Z., Hao, X.-P., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.045 · Cited by 42
Li, Y., Huan, C., Sun, H., Zhang, W., Guo, Z., Li, C., Yao, J., Zhang, Z., Yu, S., Dong, Q., et al. (2025) · Advanced Science · doi:10.1002/advs.202514661 · Cited by 47
Self-citation
Metadata
- Authors
- Wang, C., Chen, Z., Yi, Y., Ding, Y., Xu, F., Kang, H., Lin, K., Shu, X., Zhong, Z., Zhang, Z., Liu, J., Xu, Z., Liu, L., He, X., Chang, Y., & Zhao, Q.
- Affiliations
- Zhongnan Hospital of Wuhan University (CN)
- Wuhan University (CN)
- Corresponding author
- He, Xingxing
- Chang, Ying
- Zhao, Qiu
- ORCID
- Venue
- Oncogene
- Published
- 2023-12-01
- Volume
- 43
- Issue
- 5
- Pages
- 328-340
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W4389225526
- Cited by
- 42
- References
- 61
- Citations by year
- 2026: 18 · 2025: 18 · 2024: 6
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Oncogene (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82172983, 82073095, 81870390, 81670554)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- hepatocellular carcinoma, lipid metabolism reprogramming, Rictor, mTORC2, ACSL1, ACSL4, de novo lipogenesis, fatty acid beta-oxidation, CPT1A, PI3K/AKT/mTOR pathway, sorafenib combination therapy, body mass index, RNA-binding motif protein, hepatocarcinogenesis
- MeSH terms
- Sorafenib, Phosphoinositide-3 Kinase Inhibitors, Animals, Coenzyme A Ligases, Fatty Acids, Carcinoma, Hepatocellular, Humans, Lipids, Liver Neoplasms, Nerve Tissue Proteins, Transcription Factors, Signal Transduction, RNA-Binding Proteins, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Lipid Metabolism, Proto-Oncogene Proteins c-akt, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4. https://app.cochat.ai/papers/10.1038/s41388-023-02902-4
- The paper
- Wang, C., Chen, Z., Yi, Y., Ding, Y., Xu, F., Kang, H., Lin, K., Shu, X., Zhong, Z., Zhang, Z., Liu, J., Xu, Z., Liu, L., He, X., Chang, Y., & Zhao, Q. (2024). RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4. Oncogene. https://doi.org/10.1038/s41388-023-02902-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.